May 2nd 2024
Acalabrutinib plus bendamustine and rituximab bettered progression-free survival over bendamustine and rituximab alone in patients with untreated mantle cell lymphoma.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Ibrutinib Survival Outcomes in MCL Consistent in Real-World Setting, But Questions Remain
March 11th 2019Jeff Sharman, MD, discusses the implications of real-world ibrutinib findings in mantle cell lymphoma and underscored the need for the development of more effective treatments for this patient population.
Read More
Patients With MCL May Benefit From Observation Strategy
March 8th 2019Although prognostic indices for mantle cell lymphoma can be useful in the classification of patients, it does little in guiding treatment decisions. Instead of relying on these indices, Simon Rule, MD, advocates for a watch-and-wait approach to managing certain patients with mantle cell lymphoma.
Read More
MCL Field Gaining Better Understanding of Patient Subsets to Guide Treatment
March 5th 2019Andre Goy, MD, discusses some of the recent changes that have been seen in the treatment landscape for patients with MCL and some of the ways these subsets of patients are being identified in order to find the best treatment option for an individual patient.
Read More
Based on data from the phase III AUGMENT trial, a supplemental new drug application for the R<sup>2</sup> regimen of lenalidomide plus rituximab has been granted a priority review designation by the FDA as a therapy for patients with previously treated follicular lymphoma and marginal zone lymphoma.
Read More
Four-Drug Regimen Demonstrates Promising First-Line Findings for Older Patients With MCL
February 19th 2019The treatment regimen of rituximab, bendamustine, bortezomib, and dexamethasone demonstrated activity and a manageable safety profile as a first-line therapy for patients with mantle cell lymphoma aged 65 years or older, according to findings from a prospective, multicenter phase II study.
Read More
Ibrutinib and Palbociclib Combination Active in Previously Treated MCL
February 19th 2019The combination of ibrutinib and palbociclib appeared to be a feasible and active treatment regimen in patients with previously treated mantle cell lymphoma, according to findings from a phase I dose-finding study recently published in <em>Blood</em>.<sup> </sup>
Read More
Zanubrutinib Granted Breakthrough Designation From FDA for MCL
January 15th 2019The investigational BTK inhibitor zanubrutinib (BGB-3111) has received a breakthrough therapy designation from the FDA for the treatment of adult patients with mantle cell lymphoma who have previously received at least 1 prior therapy, BeiGene, the company manufacturing the agent, has announced.
Read More
Analysis Shows AHCT Leads to Improvements in PFS in Younger Patients With MCL
January 15th 2019Autologous hematopoietic cell transplantation consolidation after induction therapy may improve progression-free survival in younger, fit patients with mantle cell lymphoma, according to the results of a retrospective analysis recently published in the <em>Journal of Clinical Oncology. </em>
Read More
Cohen Considers the Role of Transplant in "Modern Era" MCL
January 14th 2019Jonathon B. Cohen, MD, MS, discussed his treatment considerations and decisions for treating patients with mantle cell lymphoma. Cohen made these decisions based on a case scenario of a patient with advanced-stage MCL.
Read More
Cohen Highlights the Factors That Influence Treatment Choice in Case Study of Advanced cHL
December 28th 2018During a <em>Targeted Oncology</em> live case-based peer perspectives presentation, Jonathon B. Cohen, MD, MS, recently discussed the treatment considerations and decisions he makes when treating patients with classical Hodgkin Lymphoma
Read More
Encouraging Responses Seen With Selinexor in Relapsed/Refractory DLBCL
December 19th 2018According to findings from the phase IIb SADAL study, selinexor demonstrated deep and durable responses in patients with relapsed/refractory diffuse large B-cell lymphoma who are not candidates for autologous stem cell transplantation.
Read More
Utilizing Circulating Tumor DNA as a Predictor of Treatment Response in MCL
December 18th 2018Measuring circulating tumor DNA in the blood of patients with advanced MCL may be a viable way to predict how well they will respond to specific therapies, according to study findings reported at the 2018 ASH Annual Meeting.
Read More
Subgroup Analysis Highlights Brentuximab Vedotin Benefit in Nonpediatric AYA Hodgkin Lymphoma
December 17th 2018In findings reported during the 2018 ASH Annual Meeting, brentuximab vedotin with conventional chemotherapy significantly improved progression-free survival compared with standard therapy for nonpediatric patients with stage III/IV Hodgkin lymphoma.
Read More
Rationale for Combining Acalabrutinib With Bendamustine and Rituximab in MCL
December 15th 2018Tycel J. Phillips, MD, assistant professor at the University of Michigan Cancer Center, discusses an ongoing trial looking at acalabrutinib plus bendamustine and rituximab in patients with treatment-naive or relapsed/refractory mantle cell lymphoma.
Watch
Shift in MCL Induction Therapy Has Led to Improvement in Event-Free Survival in Real World
December 13th 2018The shift in the pattern of care in mantle cell lymphoma to bendamustine and rituximab in the frontline has resulted in an improvement in event-free survival compared with the era in which R-CHOP dominated front-line treatment.
Read More
Acalabrutinib Regimen Demonstrates Promising Response Rates in MCL
December 11th 2018Combination therapy with acalabrutinib plus bendamustine and rituxumab showed an overall response rate in excess of 90% of patients with treatment-naïve mantle cell lymphoma and an ORR of 85% in patients with relapsed/refractory disease in an ongoing open-label phase Ib study.<sup> </sup>The safety profile was consistent with expected safety profiles for acalabrutinib and BR, said Tycel Phillips, MD, who presented the data at the 2018 American Society of Hematology Annual Meeting.
Read More
Brentuximab Vedotin Demonstrates Survival Benefit Over CHOP in CD30+ PTCL
December 6th 2018According to findings from the phase III ECHELON-2 trial presented at the 2018 ASH Annual Meeting, the use of brentuximab vedotin (Adcetris) in combination with chemotherapy demonstrated a clinically meaningful improvement in progression-free survival and overall survival in patients with CD30-expressing peripheral T-cell lymphoma. These data were also published online in <em>Lancet Oncology</em>.
Read More
Durable Responses Achieved With Acalabrutinib in MCL
December 4th 2018Durable responses were achieved with acalabrutinib therapy for patients with relapsed/refractory mantle cell lymphoma, with 40% still on treatment for more than 2 years, according to long-term follow-up findings presented at the 2018 ASH Annual Meeting.
Read More
High Response Rate Found in Relapsed/Refractory MCL With Zanubrutinib
December 3rd 2018Zanubrutinib induced an overall response rate of 83.5% in patients with relapsed/refractory mantle cell lymphoma, with many responses demonstrating durability, according to the results of a phase II trial.<br />
Read More
FDA Approves Rituximab Biosimilar for Treatment of Non-Hodgkin Lymphoma
November 29th 2018The FDA has granted approval to the rituximab (Rituxan) biosimilar, CT-P10 (Truxima; rituximab-abbs), for the treatment of adult patients with CD20-positive, B-cell non-Hodgkin lymphoma (NHL) as a single agent or in combination with chemotherapy, making it the first biosimilar approved by the FDA for the treatment of patients with NHL.
Read More
VR-CAP Regimen Improves Survival Over R-CHOP in Mantle Cell Lymphoma
November 21st 2018Using the VR-CAP regimen instead of R-CHOP significantly improved median overall survival in previously untreated newly diagnosed patients with mantle cell lymphoma who were not eligible for transplant, according to results from the long-term follow-up phase of a randomized, open-label, phase III trial.
Read More
Combinations and CAR T Cells Fulfill Unmet Need in MCL
November 20th 2018According to Robert Dean, MD, BTK inhibitors and CAR T cells may fulfill an unmet need in patients with mantle cell lymphoma. Experts have been hard-pressed to find long-lasting treatments like these that have the potential to impact this patient population.
Read More